Holen Sie sich die Stockscreener-App
2.95
0.85%
0.025
Vorhandelsmarkt:
2.97
0.02
+0.68%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.925
Offen:
$2.96
24-Stunden-Volumen:
7.05M
Relative Volume:
1.55
Marktkapitalisierung:
$905.86M
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
59.00
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
-15.71%
1M Leistung:
-48.96%
6M Leistung:
-44.76%
1J Leistung:
-42.72%
1-Tages-Spanne:
$2.865
$3.01
1-Wochen-Bereich:
$2.83
$3.72
52-Wochen-Spanne:
$2.83
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.95 | 898.18M | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets - Finviz
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
MannKind (NASDAQ:MNKD) Sets New 1-Year LowHere's What Happened - MarketBeat
MannKind (NASDAQ: MNKD) CFO adds 5,000 shares via stock purchase plan - Stock Titan
MannKind (MNKD) director adds 12,000 shares via Market Price Stock Purchase Plan - Stock Titan
MannKind (MNKD) director reports vesting of 45,025 performance-based stock options - Stock Titan
MannKind (MNKD) CEO gains stock and option vesting on milestones - Stock Titan
MannKind (NASDAQ:MNKD) Stock Price Down 6.6% After Analyst Downgrade - MarketBeat
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook By Investing.com - Investing.com Canada
H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook - Investing.com
RBC Capital downgrades MannKind stock rating on royalty concerns By Investing.com - Investing.com Canada
RBC Capital downgrades MannKind stock rating on royalty concerns - Investing.com
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
MannKind Corp. Hits New 52-Week Low at $2.94 Amid Declining Stock Performance - Markets Mojo
MannKind Corporation (MNKD): A Bull Case Theory - Finviz
MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About MannKind Corp (MNKD) - GuruFocus
MNKD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MNKD: RBC Capital Downgrades MannKind with Price Target Cut by 5 - GuruFocus
What's Going On With MannKind Stock Friday? - Benzinga
MNKD: HC Wainwright & Co. Lowers Price Target to $8.00 | MNKD St - GuruFocus
Reassessing MannKind (MNKD) After Sharp Recent Share Price Declines - Yahoo Finance
MNKD Should I Buy - Intellectia AI
Why MannKind Stock Tumbled on Thursday - Yahoo Finance
MannKind at Oppenheimer Conference: Strategic Insights for 2026 - Investing.com
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Earnings call transcript: MannKind Q4 2025 results show mixed performance By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead By Investing.com - Investing.com South Africa
MannKind Q4 2025 presentation shows 46% revenue surge, key catalysts ahead - Investing.com
Earnings call transcript: MannKind Q4 2025 results show mixed performance - Investing.com
MannKind hits 52-week low on Q4 earnings miss (MNKD:NASDAQ) - Seeking Alpha
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026 - ChartMill
Earnings Flash (MNKD) MannKind Corporation Reports Q4 Revenue $112.0M, vs. FactSet Est of $97.6M - marketscreener.com
MANNKIND ($MNKD) Releases Q4 2025 Earnings - Quiver Quantitative
MannKind: Fourth Quarter Earnings Overview - Bitget
MannKind: Q4 Earnings Snapshot - marketscreener.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corporation Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Caledonian Record
MannKind Earnings Review: Q4 Summary - Benzinga
MannKind (NASDAQ:MNKD) Reaches New 1-Year LowShould You Sell? - MarketBeat
United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook - simplywall.st
MNKD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
MNKD MannKind (NASDAQ): Shares slide 36.82% to $3.50 pre-earnings, catalyst to watch - Meyka
MannKind Corp stock hits 52-week low at $3.36 By Investing.com - Investing.com Australia
MannKind stock plummets after partner United Therapeutics unveils new 'category killer product' - MSN
MannKind (MNKD) Shares Plummet Amid United Therapeutics Announcement - GuruFocus
MannKind (MNKD) Sees Stock Drop After Competitor's Product Devel - GuruFocus
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):